- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1595KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 413KB)
Fulvestrant – July 2020
Fulvestrant: Injection 250 mg in 5 mL pre-filled syringe; Faslodex®
Last updated
30 October 2020